120 related articles for article (PubMed ID: 8327439)
21. Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine L3 adjuvant protects against tuberculosis.
Haile M; Schröder U; Hamasur B; Pawlowski A; Jaxmar T; Källenius G; Svenson SB
Vaccine; 2004 Mar; 22(11-12):1498-508. PubMed ID: 15063575
[TBL] [Abstract][Full Text] [Related]
22. Vaccination of cattle with Mycobacterium bovis culture filtrate proteins and CpG oligodeoxynucleotides induces protection against bovine tuberculosis.
Wedlock DN; Skinner MA; de Lisle GW; Vordermeier HM; Hewinson RG; Hecker R; van Drunen Littel-van den Hurk S; Babiuk LA; Buddle BM
Vet Immunol Immunopathol; 2005 Jun; 106(1-2):53-63. PubMed ID: 15910992
[TBL] [Abstract][Full Text] [Related]
23. [Study of a role of artificial mycobacterial particles in the realization of immunological processes in experimental animal tuberculosis].
Azaev MSh; Lebedev LR; Kuz'micheva GA; Tumanov IuV; Donchenko NA; Tat'kov SI; Nosareva OV; Il'ichev AA
Probl Tuberk Bolezn Legk; 2007; (2):38-42. PubMed ID: 17419334
[TBL] [Abstract][Full Text] [Related]
24. Pathogenesis of pulmonary Mycobacterium bovis infection: basic principles established by the rabbit model.
Dannenberg AM
Tuberculosis (Edinb); 2001; 81(1-2):87-96. PubMed ID: 11463228
[No Abstract] [Full Text] [Related]
25. Oral delivery of lipid-encapsulated Mycobacterium bovis BCG extends survival of the bacillus in vivo and induces a long-term protective immune response against tuberculosis.
Aldwell FE; Cross ML; Fitzpatrick CE; Lambeth MR; de Lisle GW; Buddle BM
Vaccine; 2006 Mar; 24(12):2071-8. PubMed ID: 16332403
[TBL] [Abstract][Full Text] [Related]
26. The influence of remaining live BCG organisms in vaccinated mice on the maintenance of immunity to tuberculosis.
Olsen AW; Brandt L; Agger EM; van Pinxteren LA; Andersen P
Scand J Immunol; 2004 Sep; 60(3):273-7. PubMed ID: 15320884
[TBL] [Abstract][Full Text] [Related]
27. Development of a simple, sensitive, rapid test which discriminates BCG-vaccinated from Mycobacterium bovis-infected cattle.
Sopp P; Coad M; Hewinson G; Howard CJ; Cheallaigh CN; Keane J; Harris J; Hope JC
Vaccine; 2008 Oct; 26(43):5470-6. PubMed ID: 18692540
[TBL] [Abstract][Full Text] [Related]
28. Comparative immunogenicity of BCG substrains for mice.
Júnior LP; Gontijo Filho PP
Rev Bras Pesqui Med Biol; 1979 Sep; 12(4-5):311-6. PubMed ID: 394227
[TBL] [Abstract][Full Text] [Related]
29. [Level and spectrum of tuberculosis antibodies in mice sensitive and resistant to tuberculosis].
Litvinov VI; Markov AN; Nikonenko BV; Chernousova LN; Dem'ianenko NV; Safonova SG
Probl Tuberk; 1993; (2):53-5. PubMed ID: 7984575
[TBL] [Abstract][Full Text] [Related]
30. Immunogenicity of Mycobacterium bovis BCG expressing Anaplasma marginale MSP1a antigen.
Michelon A; Conceição FR; Binsfeld PC; da Cunha CW; Moreira AN; Argondizzo AP; McIntosh D; Armôa GR; Campos AS; Farber M; McFadden J; Dellagostin OA
Vaccine; 2006 Sep; 24(37-39):6332-9. PubMed ID: 16781025
[TBL] [Abstract][Full Text] [Related]
31. Vaccination of cattle with Danish and Pasteur strains of Mycobacterium bovis BCG induce different levels of IFNgamma post-vaccination, but induce similar levels of protection against bovine tuberculosis.
Wedlock DN; Denis M; Vordermeier HM; Hewinson RG; Buddle BM
Vet Immunol Immunopathol; 2007 Jul; 118(1-2):50-8. PubMed ID: 17524495
[TBL] [Abstract][Full Text] [Related]
32. Expanding the antigenic repertoire of BCG improves protective efficacy against aerosol Mycobacterium tuberculosis infection.
Palendira U; Spratt JM; Britton WJ; Triccas JA
Vaccine; 2005 Feb; 23(14):1680-5. PubMed ID: 15705472
[TBL] [Abstract][Full Text] [Related]
33. Mycobacterium avium subsp. paratuberculosis-specific mpt operon expressed in M. bovis BCG as vaccine candidate.
Heinzmann J; Wilkens M; Dohmann K; Gerlach GF
Vet Microbiol; 2008 Aug; 130(3-4):330-7. PubMed ID: 18343053
[TBL] [Abstract][Full Text] [Related]
34. Vaccination of neonatal calves with Mycobacterium bovis BCG induces protection against intranasal challenge with virulent M. bovis.
Hope JC; Thom ML; Villarreal-Ramos B; Vordermeier HM; Hewinson RG; Howard CJ
Clin Exp Immunol; 2005 Jan; 139(1):48-56. PubMed ID: 15606613
[TBL] [Abstract][Full Text] [Related]
35. Schistosoma mansoni infection reduces the protective efficacy of BCG vaccination against virulent Mycobacterium tuberculosis.
Elias D; Akuffo H; Pawlowski A; Haile M; Schön T; Britton S
Vaccine; 2005 Feb; 23(11):1326-34. PubMed ID: 15661380
[TBL] [Abstract][Full Text] [Related]
36. [Novel vaccines against M. tuberculosis].
Okada M
Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
[TBL] [Abstract][Full Text] [Related]
37. Delayed type hypersensitivity and antituberculous immunity.
Averbakh MM; Gergert VY; Kluyev VA; Kolodiazhnaya NS; Litvinsov VI; Moroz AM
Z Immunitatsforsch Exp Klin Immunol; 1974 Aug; 147(3):204-16. PubMed ID: 4283014
[No Abstract] [Full Text] [Related]
38. [Immunological tolerance and antituberculosis immunity].
Averbakh MM; Litvinov VI; Markov AN; Il'ina NN
Biull Eksp Biol Med; 1980 Feb; 89(2):198-200. PubMed ID: 7370422
[TBL] [Abstract][Full Text] [Related]
39. The ultrastructure of the strain BCG 725 cultivated on Sauton's medium with casein hydrolysate. Co-report the report "biochemistry of BCG lipids and their role in antituberculous immunity and hypersensitivity.
Mohelská H
J Hyg Epidemiol Microbiol Immunol; 1975; 19(4):453-7. PubMed ID: 1107418
[No Abstract] [Full Text] [Related]
40. Modulating effect of passive immunization with anti-Mycobacterium tuberculosis antibodies on humoral response in BCG-infected mice.
Gros P; Forget A
Int Arch Allergy Appl Immunol; 1980; 63(4):446-54. PubMed ID: 6776065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
